Embed Size (px)
Citation preview
Update on clinical studies in Belgium
Jacques De Grève MD, PhD
Medical Oncology
Oncologisch Centrum
Observations
Some academic, many “commercial”
Profile similar between large community hospitals and academic hospitals, except for initiating translational studies
Phase I-III and post-marketing The latter are often (masked) drug-pushing studies
Some increasing cross-center cooperation Which is very good
Very little non-drug research activity Surgical or radiotherapy
Caution
Confidential
Biased overview
Information requested from 25 sources
Information obtained from 12 investigators/centers
Overview
Prevention
Surgical
Neoadjuvant
Adjuvant Hormonal
HER2 positive
Chemotherapy
Molecular
Metastatic Hormonal
HER2 positive
Chemotherapy
Molecular
Prevention
IBIS studies:
Role of AI in BC prevention in high risk profiles
Some scientific value, but impact on clinical
practice improbable because of anticipated
Financial+toxicity cost
Efficacy= ASTRONOMICAL
Familial breast cancer
Search for novel breast
cancer predisposing
genes
Better method for
counseling
BARD
1
>1
J. De Grève et al, Current Opinion in Oncology, 11, 2008
UZBrussel
Copyright ©2004 BMJ Publishing Group Ltd.
Sermijn, E et al. J Med Genet 2004;41:e23
Awareness of the existence of a BRCA mutation in the subject's own family
Families ill-informed
Half of all pre-symptomatic mutation carriers
do not engage in cancer prevention
Screening 50%
BSO (all) 57.2%
PM (No BC) 18%
Chemoprevention (No mastectomy) 8.4%
No action (No BC) 50%
Half of mutation carriers do nothing
Prospective study
Organized an active information of relevant family members on existence of mutation and subsequent prevention
Efficacy and psychological impact
E.Sermijn/M. Goossens, UZBrussel
SURGERY
Surgery
Pedicled Perforator Flaps
Since 1989, major advance for reconstructive
surgery
Only skin and subcutaneous tissue is utilized for
reconstruction of defects with preservation of fascia,
muscles and nerves according to basic plastic
surgical principle of ” replacing like with like “
Muscle left in its native place to serve its original
function and minimize donor site morbidity
Thoracodorsal artery perforator (TDAP) flap
Second generation perforator flaps Hamdi M, et al.
Pedicled perforator flaps in breast reconstruction: a new concept. Br. J. Plast. Surg. 2004 Sep; 57(6): 644-52
Other Thoracodorsal artery perforator (TDAP) flap
Intercostal artery perforator (ICAP) flap
Serratus anterior artery perforator (SAAP) flap
Superior epigastric artery perforator (SEAP) flap
BJMO review (coming)
UGent
Indications
Immediate or delayed partial breast reconstruction
following tumorectomy/ quadrantectomy
Post-mastectomy breast reconstruction in
combination with an implant
Reconstruction of shoulder and thoracic defects
after oncological resections
Should replace the classical latissimus dorsi
flap in many indications in breast surgery
Satisfied women
Adjuvant radiotherapy
EORTC SUPREMO 22051-10052
Phase III randomized trial
Role of adjuvant chest wall irradiation in
“intermediate risk” breast cancer
following mastectomy
http://www.eortc.be
D. Vanden Wyngaert, ZNA
Neoadjuvant
Aout 2008
FRAGRANCE TRIAL
Postmenopausal patients (no age limits)
Non-candidates for CT
T 2 cm
Stages I, II & III
ER and/or PgR+
Letrozole 4 to 6 months
S
U
R
G
E
R
Y
Frozen
Biopsy 1
D15D0
Frozen
Biopsy 2
(optional)
Frozen Biopsy 3
• F. Cardoso
• Lab: M. Gloeckel, C. Desmedt,
V. Durbecq, C. SotiriouBiomarkers for response to AI
RANDOMIZE
NEO-ALTTO
Stratification:—T< 5 cm versus T> 5 cm—ER or PgR + versus both
ER and PgR –—N0-1 versus N ≥2—Conservative surgery or not
lapatinib
trastuzumab
lapatinib
trastuzumab
paclitaxel
paclitaxel
paclitaxel
Surgery
FEC
3
lapatinib
trastuzumab
lapatinib
trastuzumab
18 weeks 9 weeks 34 weeks
52 weeks of anti-ErbB2 therapy
Invasive breast cancerHER2+ T>2 cm (inflammatory BC excluded)
LVEF 50%
N=450
Biomarkers for response
Adjuvant
Adjuvant studies
SOLE
IBCSG 35-07 / BIG 1-07
Postmenopausal women with HR positive, N+ early stage breast cancer
Phase III trial of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant endocrine therapy
N=4600
Guy Jerusalem, Liège
Rationale
ER+ cancers relapse continuously
Extended adjuvant results
Adjuvant tamoxifen: 10 years is better than 5
years
AI reimbursed for 5 years or extended
adjuvant
N+
Hormonal adjuvant
EORTC 10031(SOFT)
• Premenopausal 35y
• Tamoxifen
vs
• OFS + tamoxifen
vs
• OFS + exemestane
Adjuvant studies
ALTTO
Lapatinib dual EGFR/HER2 neu inhibitor EGFR effect irrelevant in BC
Good drug after H failure, especially with BM‟s
A randomised phase III comparison Adjuvant lapatinib, trastuzumab, their sequence and their
combination in patients with HER2/ErbB2 positive primary breast cancer
Open Q how efficacies versus toxicities will differ
BIG 2-06/N063D/DGF106708
•Patients with ER or PgR-positive tumours receive endocrine therapy selected accordingly to menopausal status; endocrine therapy will be started
after the end of chemotherapy, will be administered concurrently with targeted therapies and will be planned for at least 5 years
• Radiotherapy if indicated
DESIGN 1: Completion of ALL (neo)adjuvant chemotherapy prior to targeted therapy
Trastuzumab3-weekly
(For 52 weeks)
Lapatinib
(For 52 weeks)
Trastuzumab Weekly
(For 12 weeks)
Lapatinib
3-weekly
+Trastuzumab (For 52 weeks)
Centrally-determined HER2 +
Surgery, complete (neo)adjuvant anthracycline-based chemotherapy (selected from an approved list)
LVEF 50%
Locally-determined HER2-positive invasive breast cancer
Washout (6 weeks)
Lapatinib (34 weeks)
ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization) study
Locally-determined HER2-positive invasive breast cancer
Centrally-determined HER2 +
Surgery, complete (neo)adjuvant chemotherapy(selected from an approved list)
LVEF 50%
52
W
EE
KS
Lapatinib
+
Trastuzumab
3-weekly
40 weeks
Lapatinib
+
Trastuzumab
Weekly
12 weeks
Trastuzumab
Weekly
12 weeks
Lapatinib
52 weeks
3-weekly
Trastuzumab
40 weeks
Lapatinib
34 weeks
Paclitaxel
Weekly
12 weeks
+/-
Radio-
therapy
Paclitaxel
Weekly
12 weeks
+/-
Radio-
therapy
Paclitaxel
Weekly
12 weeks
+/-
Radio-
therapy
Washout 6
weeks
DESIGN 2: Paclitaxel concurrent with targeted therapy after any A-based (neo)adjuvant CT
Paclitaxel
Weekly
12 weeks
+/-
Radio-
therapy
Trastuzumab
Weekly
12 weeks
ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) study
Adjuvant studies
MINDACT
EORTC 10041 BIG3-04 Fatima Cardoso/ Martine Piccart
Can microarray expression profiling help avoid chemotherapy in N- disease?
Phase III
Compares the 70-gene expression signature with common clinical-pathological criteria in selecting patients for adjuvant chemotherapy in node-negative breast cancer
Aout 2008
Evaluate Clinical-Pathological risk and 70-gene signature risk
Clinical-pathological
and 70-gene both
HIGH risk
Discordant cases
Clin-Path HIGH
70-gene LOW
Clin-Path LOW
70-gene HIGH
Clinical-pathological
and 70-gene both LOW
risk
Use Clin-Path risk to decide
Chemo or not
Use 70-gene risk to decide
Chemo or not
55%32% 13%
R1
Chemotherapy
N=3300 N=780
Endocrine therapy
EORTC-BIG MINDACT TRIAL DESIGN
6,000 Node negative women
N=1920
MD: M. Piccart; F. Cardoso;
HER2+ adjuvant
BACH study
Caelyx-endoxan-herceptin
vs
AC -> taxol-herceptin
+ cardiac substudy strain rate
UZLeuven
Beatrice
International multi-centre phase III trial of
adjuvant Bevacizumab in triple negative
breast cancer
Beatrice
Aout 2008
LOCAL RELAPSE [IBCSG 27-02, BIG 1-02]Chemotherapy for Radically Resected Loco-regional Relapse
R
ANDOMIZE
S
U
R
G
E
R
Y
Strata:
-Prior CT
-ER+ and/or
PgR+
-Location of
recurrence
Observation(+/- Radiation Therapy)
Chemotherapy(+/- Radiation Therapy)
ER+ and/or PgR+:
hormonal therapy
ER+ and/or PgR+:
hormonal therapy
Recrutement total prévu: 977 patientes
(MD: F. Cardoso)
« PSEUDO-ADJUVANT »
Metastatic
Hormones
HR+ MBC
IGF1-receptor targeting
IGF1R important co-regulator of other GF
pathways and endocrine pathways, including
causing resistance
CP-751,871 = IGF1R Moab Pfizer
Multiple myeloma:
9/ 27 RR in combination with dexamethasone
2 PR in dexa resistant patients
HR+ MBC
IGF1-receptor targeting
RANDOMIZED PHASE 2 in 1st-line
COMBINATION WITH EXEMESTANE
vs
EXEMESTANE ALONE AS FIRST LINE
Hans Wildiers
Copyright ©2007 AlphaMed Press
Stanway, S. J. et al. Oncologist 2007;12:370-374
Steroidogenesis in postmenopausal women and site of action of STX64 (BN83495)
• Steroid sulfatase (STS) activity much higher than aromatase activity in breast tumors
• High levels of STS mRNA associated with a poor prognosis
• STS hydrolyzes steroid sulfates, such as estrone sulfate and dehydroepiandrosterone sulfate (DHEAS), to estrone and DHEA, which can be converted to steroids with potent estrogenic properties, that is, estradiol and androstenediol, respectively.
Jan 2008
Steroid sulfatase inhibitor
• Post-menopausal with ER positive, LABC or MBC
• 2nd line HT (adjuvant HT allowed but progressed > 12 ms)
• Only 1 prior CT and Herceptin (discontinued at least for 4 months prior)
• Measurable (RECIST) and non-measurable (only until OBD)
• Progressive CNS excluded
METASTATIC SETTING: HR + Hormonal TherapyIPSEN BN83495 TRIAL (Phase 1)
Bordet
HOBO-trial
Phase II study in patients with hormone
receptor positive breast cancer with
Bortezomib (Velcade) in the reversal of
endocrine resistance
L. Dirix, Sint Augustinus
Also many interesting translational studies in inflammatory breast cancer
HER2 positive disease
Metastatic disease (MBC) HER2-positive
EGF 104383
Phase III study
Paclitaxel plus Trastuzumab plus Lapatinib
vs
Paclitaxel plus Trastuzumab plus placebo
Aout 2008
Pfizer A 6181067: Herceptin + Sutent
•Phase II
•CT not indicated but Herceptin indicated
•Prior treatment with trastuzumab and/or lapatinib in the
neoadjuvant, adjuvant or metastatic setting is permitted
Pfizer A 6181113: Docetaxel + Herceptin + SU011248 (Sutent)
•Phase II
• F. Cardoso
METASTATIC SETTING
HER-2 BC 1st Line
Aout 2008
METASTATIC SETTING HER-2 BC
2nd or more Line
Local relapse and/or inflammatory MBC
Lapatinib +/- Pazopanib
Phase III randomised double blind
Must have received CT and Trastuzumab
Main endpoint: PFS
Controlled CNS mets allowed
GSK: VEG108838
HSP90
Metastatic studies HER2-positive
MedImmune Protocol No. MI-CP153
Phase 2
Antitumor Activity and Safety of IPI-504,
Small Molecule Inhibitor of Heat Shock Protein 90
(Hsp90)
Progressed on HER2-targeted Therapy
Marleen Borms, AZ Groeninge
UZLeuven
Aout 2008
METASTATIC SETTING HER-2 BC
Herceptin + Velcade
• Bordet-sponsored trial and based on their prior preclinical
experiments1
• Phase I
• No limit of previous lines of HT nor CT
• Previous Herceptin or lapatinib allowed
• All MBC HER-2 for whom Herceptin alone would be the choice
F. Cardoso
1Cardoso F, et al
Bortezomib increases the efficacy of trastuzumab (Herceptin) in
HER-2-positive breast cancer cells in a synergistic manner
Mol Cancer Ther. 2006 Dec;5(12):3042-51
Ertumaxomab
•Bispecific antibody targeting HER2/neu and CD3
•Formation of a tri-cell complex
•tumour cell, T cell and accessory cell
•Antitumour efficacy against HER2/neu low-expressing
tumours resistant to trastuzumab
• Phase I study in MBC : strong immune responses
• Phase II studies MBC even without HER2/neu gene
amplification
Aout 2008
METASTATIC SETTING
Biological Therapy Alone
HR + & HER-2 1 or 2/FISH BC
Ertumaxomab (trifunctional HER MoAb) (Fresenius)
Phase I I
HR + but HT Resistant
HER-2 + ou ++ but FISH neg
F. Cardoso
Aout 2008
METASTATIC SETTING
1. Lapatinib + Temozolomide (LAPTEM)
2. Lapatinib + Capecitabine
BRAIN METASTASES
HER-2+
Bordet
Metastatic HER2 + BC
3144A1-203-WW
HKI-272: irreversible inhibitor of EGFR/HER2neu
Phase I/II study and after Herceptin failure
HKI-272 with paclitaxel in subjects with solid tumours and breast cancer
HKI-272 (Neratinib) + Vinorelbine
AZ Groeninge en Bordet
Metastatic Triple Negative BC
BIBW 2992 (Boehringer)
• Dual irreversible EGFR/HER2neu inhibitor
• Phase II
• HER-2 Neg, HR negative (Triple Negative)
• Asymptomatic brain mets allowed
Eribulin
Synthetic analogue of halichondrin B
Substance derived from a marine sponge
(Lissodendoryx sp.)
Binds to vinca domain of tubulin and
inhibits the polymerization of tubulin
Inhibition of mitotic spindle assembly,
induction of cell cycle arrest at G2/M phase
MBC, 2nd line
E7389 (Eribulin)
Phase 3, Multiple centers
1. Eribulin versus „treatment of physician‟s choice‟ in patients with locally recurrent or metastatic breast cancer, previously treated with at least two and maximum five prior chemotherapy regimens, including an anthracycline and a taxane
2. Eribulin versus Capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes and refractory to the most recent chemotherapy
Jan 2008
METASTATIC SETTING
Triple Negative
1st Line
MERCK 20027-051 BALI-1
Phase-II randomized
• WEEKLY CETUXIMAB + six 3-WEEKLY cycles of CISPLATIN
• Maximum of six 3-WEEKLY CYCLES OF CISPLATIN
Main endpoint: RR
Only 1 prior anthracycline or taxane (adjuvant or MBC)
• MD: A. Awada
IMC-1121B
A multicenter phase III-study in first-line
Anti-vascular endothelial growth factor
receptor-2 (VEGFR-2) monoclonal antibody
IMC-1121B plus Docetaxel
vs
placebo plus Docetaxel
V. Cocquyt
SUCON trial
SUtent CONsolidation
A belgian multicenter phase II randomized trial in her2 negative
metastatic breast cancer evaluating consolidation antiangiogenic
therapy with SU11248 after response to taxane chemotherapy
induction.
H. Wildiers
SUCON trial
Biomarking in Top trial
Anthracycline in triple negative:
Looking for biomarkers for
sensitivity/resistance
Expression profiling
Genetic predisposition genes
Epigenetic profiling
Bordet-ULB-UCL-VUB
PARP1 inhibitor
High activity in genetic ovarian cancer*
Under study:
SA activity under study in genetic breast cancer
Activity with cisplatinum in breast cancer
* AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single
agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study. P. C. Fong, D. S. Boss, C. P. Carden, M. Roelvink, J. De Greve, et al
J Clin Oncol 26: 2008 (May 20 suppl; abstr 5510)
L. D. Wood et al., Science 318, 1108 -1113 (2007)
Future is: genomics
Thank you for the information
Bordet: F. Cardoso
AZ Groeninge: M. Borms
Hasselt: J. Janssens
UGent: H. Thierens, V.Cocquyt, M. Hamdi
UZBrussel: C. Fontaine
UZLeuven : H. Wildiers en P. Neven
UZAntwerpen: W. Tjalma (overview)
Klina: D. Verhoeven,
OLV-Aalst
Sint-Nicolaas
ZNA (Vandenwyngaert)
Pro
pid
ium
iod
ide
Annexin V Annexin V Annexin V
Control Fulvestrant Estradiol
B
Estrogen Induces Apoptosis and Tumor Regression in a BreastCancer Cell Line Resistant To Estrogen Deprivation
0
2
4
6
8
10
12
14
16
2 4 6 8 10
AUTONOMOUSGROWTH
ESTRADIOL
FULVESTRANT
A
DN
A (m
g/w
ell)
Days
G1-blockade Apoptosis
0.0
0.2
0.4
0.6
0 2 4 6 8
Ave
rage
tu
mo
ur
are
a (c
m2)
Weeks
AUTONOMOUSGROWTH
FULVESTRANT
ESTRADIOL
CIn vivo
In vitro
Lewis et al, J Natl Cancer Inst. 2005; 97:1746-59
Effect of intermittent letrozole treatment in MCF-7Ca xenografts
1
1
1
1
1
1
5.4
3.1
4.1
1
0.2
0.2
6.7
3.7
5.9
1
0
0.1
1.99
2.1
0.9
0.9
0.9
0.9
0.3
1.3
0.8
0.9
2.7
2.4
1.1
1.7
1.1
1
0.8
1.1
Her-2
p-Her-2
p-MAPK
MAPK
Aromatase
ERα
ß-Actin
Off Letrozole
Letrozole
0
250
500
750
1000
1250
1500
1750
2000
2250
2500
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36
Me
an T
um
or
Vo
lum
e (
mm
3)
Control
Back onLetrozole
Weeks
Sabnis et al. Cancer Res. 2008;68,4518.
Patient Population
• Postmenopausal
• Disease-free after 4 to 6 years of prior adjuvant endocrine therapy (SERM and/or AI)
• Endocrine-responsive breast cancer at diagnosis
• Node-positive breast cancer at diagnosis
S LE
• 10 of a total of 25 accepted sites in Belgium are actively recruting. Last month Belgium as a country take the lead compared to all other countries concerning the recrutment.
• The trial allows free drug access for all postmenopausal lymph node positive patients who are candidates for extended adjuvant treatment and who received an aromatase inhibitor within the first 5 years (and who consequently can not obtained a reimbursement for extended adjuvant treatment).
• Contact: [email protected]
Patient Visit Schedule
• All patients will be followed every 6 months for years 1 to 5, and thereafter yearly for assessment of disease status and for survival data collection.
S LE
Aout 2008
« EN PRATIQUE »: ADJUVANT
Phase III trial (4800 pts): 5 years continuous letrozole vs of intermittent
letrozole following 4 to 6 years of prior adjuvant HT (tam and/or AI)
Postmenopausal women with HR positive; Node positive only
Main endpoint: DFS; tumor block required; QoL substudy
Participating centers2-2006: 15 centres
• UZ Gasthuisberg Leuven (R Paridaens and H Wildiers and P Neven)
• AZ St-Augustinus Wilrijk (L Dirix)
• Imelda Bonheiden (W. Wynendaele)
• AZ St jan Brugge (E. Decuypere)
• ZOL (J Mebis, D Luyten, G Debrock)
• St-Elisabeth Turnhout (M Martens)
• St-Elisabeth Namen (P Vuylsteke and Jean-Charles Goemine)
• UZ Gent (H Denys and Dr V Cocquyt)
• UCL Brussels and Mont-Godinne (JP Machiels and J Kerger)
• Charleroi (JL Canon)
• UZBrussel (J De Greve)
• Liege (G Jerusalem)
8-2007: 5 new centres
• Cliniques du Sud-Luxembourg, Arlon (P Glorieux)
• CHR de Huy (J Collignon, J Bury, M Reginster)
• CHC Clinique Saint Joseph (C Focan, M P Graas, F Kreutz)
• UCL Ottignies Louvain-la-Neuve (L Duck)
• AZ Nikolaas (W Lybaert, I Deleu, E Everaert)
Aout 2008
METASTATIC SETTING
HER-2 Neg BC
1st Line MBC
WX-671 + Capecitabine vs. Placebo + Capecitabine (Wilex)
Phase II randomised
Main endpoint: PFS
Measurable disease (RECIST)
Bone or skin only not allowed
SNS mets not allowed
• F. Cardoso
Serine protease inhibitor inhibits the uPA system
